Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Aldeyra Therapeutics Inc.

Aldeyra Therapeutics ($ALDX) told investors its dry eye drug reproxalap was showing strong, consistent results across multiple late-stage trials. F...

Aldeyra Therapeutics Sued Over Alleged Misrepresentations About Key Drug Trial Data

The latest update is out from Aldeyra Therapeutics ( ($ALDX) ). Aldeyra Therapeutics, Inc. previously entered into a Loan and Security Agreement in...

Aldeyra Repays Hercules Loan, Boosting Financial Flexibility

Traders will find the top stock market stories for Tuesday in our daily wrap-up.


Morning News Wrap-Up 3/17/26: Today’s Biggest Stock Market Stories!

Aldeyra Therapeutics ( ($ALDX) ) has shared an update. On March 17, 2026, Aldeyra Therapeutics announced that the U.S. Food and Drug Administration...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ALDX	$1.56	+2.63%	1.09M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ALDX	$1.56	+2.6%	1.09M
3
4
5
6

ALDX

ALDX

Get Aldeyra Therapeutics Inc. Data in Excel

Get Aldeyra Therapeutics Inc. Data in Excel